Eli Lilly and Company /
Adverum Biotechnologies, Inc.
Eli Lilly and Company agrees to buy Adverum Biotechnologies, Inc.




Source for the buyer and target: Adverum Biotechnologies, Inc.
For the buyer and target.
“As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 24, 2025, Adverum Biotechnologies, Inc., a Delaware corporation (“Adverum” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of October 24, 2025, by and among the Company, Eli Lilly and Company, an Indiana corporation (“Parent”), and Flying Tigers Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”).”
Published 9 Dec 2025
Open the sourceWhat happened
Eli Lilly and Company agreed to acquire Adverum Biotechnologies, Inc., according to a filing dated Dec. 9, 2025. [01]
Who is involved, and the source
Everything on this page comes from the source below, quoted word for word.
Advisers
Target
- Fairness opinion to the targetAquilo PartnersSource: SEC filing, as of 7 Nov 2025
- Financial adviser to the targetAquilo PartnersSource: SEC filing, as of 7 Nov 2025
Each adviser in its source's own words. An adviser's own announcement is labelled as one: it is not independent reporting. Advisers are not parties to the deal.
Eli Lilly and Company agrees to buy Adverum Biotechnologies, Inc.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Announced
“Eli Lilly and Company agrees to buy Adverum Biotechnologies, Inc. Eli Lilly and Company agreed to acquire Adverum Biotechnologies, Inc., according to a filing dated Dec. 9, 2025”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly